The present invention is based, in part, on the discovery that endogenous mRNAs can be recruited for translational repression of target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means by which to treat genetic (e.g., genetic neurodegenerative diseases such as Huntington's Disease) or non-genetic diseases by, for example, blocking the synthesis of proteins that contribute to the diseases. Accordingly the RNA-silencing agents of the present invention have an mRNA targeting moiety, a linking moiety, and an mRNA recruiting moiety.

 
Web www.patentalert.com

< IRNA agents with biocleavable tethers

< Inhibitor nucleic acids

> Oxidized reversibly swelling granular starch products

> Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained

~ 00220